DCT

1:25-cv-01262

Bayer Healthcare Pharma Inc v. Apotex Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-01262, D. Del., 10/15/2025
  • Venue Allegations: Venue is alleged to be proper for Apotex Inc., a foreign corporation, because it is subject to personal jurisdiction in the district. Venue is alleged to be proper for Apotex Corp. because it is a Delaware corporation.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of the drug KERENDIA® (finerenone) constitutes an act of infringement of a patent covering a specific crystalline form of the active ingredient and the method of its preparation.
  • Technical Context: The lawsuit is in the field of pharmaceutical process chemistry, focusing on a patented method for scalable manufacturing and purification of a specific crystalline polymorph of finerenone, a non-steroidal mineralocorticoid receptor antagonist.
  • Key Procedural History: This is a Hatch-Waxman action triggered by Defendants' Paragraph IV certification asserting that the patent-in-suit is invalid, unenforceable, and/or will not be infringed by their proposed generic product. The patent-in-suit, RE'826, is a reissue of U.S. Patent No. 10,336,749, with the reissued patent containing a modified claim set (claims 14-30).

Case Timeline

Date Event
2015-08-21 RE'826 Patent Priority Date
2019-07-02 Original U.S. Patent No. 10,336,749 Issue Date
2021-07-09 FDA Approval of KERENDIA® (NDA No. 215341)
2024-02-06 U.S. Reissue Patent No. RE49,826 Issue Date
2025-09-05 Apotex sends Paragraph IV Notice Letter to Bayer
2025-09-08 Bayer receives Apotex's Paragraph IV Notice Letter
2025-10-15 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 49,826 - "Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient"

  • Patent Identification: U.S. Reissue Patent No. 49,826, "Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient," issued February 6, 2024 (the "RE'826 Patent").

The Invention Explained

  • Problem Addressed: The patent's background describes the prior "research scale synthesis" of the finerenone compound as being unsuitable for industrial, large-scale manufacturing. The prior art process suffered from a low overall yield, required multiple "laborious" chromatographic purifications, used excessive amounts of reagents, and proceeded at very high dilutions, making it inefficient and costly for commercial production RE'826 Patent, col. 1:47-63
  • The Patented Solution: The patent discloses a "novel and improved process" that enables the efficient, reproducible, and scalable synthesis of the finerenone compound, specifically in a defined crystalline form known as "polymorph I" RE'826 Patent, col. 1:64 - col. 2:5 RE'826 Patent, col. 13:58-65 The new process streamlines production into four stages with a significantly higher overall yield and, critically, avoids the need for chromatographic purification of intermediates by using a specific final crystallization step that isolates the desired polymorph with high purity RE'826 Patent, col. 3:61-68 RE'826 Patent, col. 14:1-25
  • Technical Importance: The invention provides an economically viable and industrially practicable method to produce a highly pure, stable, and defined crystalline form of a pharmaceutical active ingredient, which is a critical requirement for regulatory approval and commercial drug manufacturing RE'826 Patent, col. 1:64-68

Key Claims at a Glance

  • The complaint asserts claims 14-30 of the RE'826 Patent Compl. ¶45
  • Independent Claim 14 is a product claim directed to:
    • A compound of the formula (I)
    • in crystalline form of polymorph I
    • wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0.
  • Independent Claim 27 is a product-by-process claim directed to:
    • A compound of the formula (I) in crystalline form of polymorph I
    • prepared by a process comprising obtaining the compound of formula XIII
    • separating the compound of formula XIII by chiral separation to obtain the compound of formula I
    • dissolving, stirring, and isolating the compound of formula (I) in crystalline form of polymorph I.
  • The complaint does not specify which dependent claims may be asserted.

III. The Accused Instrumentality

Product Identification

  • Defendants' proposed generic finerenone tablets (10 mg and 20 mg), which are the subject of Abbreviated New Drug Application (ANDA) No. 220684 filed with the FDA Compl. ¶1 Compl. ¶43 The product is referred to as "Apotex's ANDA Product" Compl. ¶13

Functionality and Market Context

  • The accused product is a purported generic version of Bayer's branded drug KERENDIA®, which is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) Compl. ¶1 Compl. ¶34 It is indicated for reducing the risk of kidney disease decline, cardiovascular events, and heart failure in certain patient populations Compl. ¶34 As a generic, Apotex's product is intended to be a lower-cost, bioequivalent substitute for KERENDIA® and would compete directly with it upon receiving FDA approval Compl. ¶41

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), where the act of infringement is the submission of the ANDA itself. The theory is that the product Apotex seeks to market, if commercially manufactured, would infringe the claims of the RE'826 Patent. The complaint does not provide a detailed claim chart or specific evidence of the characteristics of Apotex's proposed product, relying instead on the premise that a bioequivalent generic must necessarily possess the properties of the patented compound.

RE'826 Patent Infringement Allegations

Claim Element (from Independent Claim 14) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of the formula (I) in crystalline form of polymorph I The complaint alleges that Apotex's ANDA Product, as a generic version of KERENDIA®, contains the active pharmaceutical ingredient finerenone (formula I) and, to be bioequivalent, must necessarily be in the claimed "crystalline form of polymorph I." ¶1; ¶41; ¶55 col. 13:58-65
wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0. The complaint alleges that the product Apotex seeks to market will infringe, which implies it will possess the physical characteristics, including the specific X-ray diffraction peaks, that define polymorph I. ¶53; ¶55 col. 14:40-44
  • Identified Points of Contention:
    • Factual Question (Polymorph Identity): The central factual dispute will be whether the finerenone active pharmaceutical ingredient in Apotex's ANDA Product is, in fact, the specific "crystalline form of polymorph I" as defined by the patent's claims. This will likely be determined through expert analysis of discovery materials, including samples of Apotex's product and its manufacturing process records.
    • Scope Question (Product-by-Process): For product-by-process claims such as claim 27, a key legal and factual question will be whether Bayer can prove that the process Apotex uses to manufacture its product meets the specific process limitations recited in the claim. Infringement of such a claim typically requires demonstrating that the accused infringer uses the claimed process.

No probative visual evidence provided in complaint.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a full analysis, but based on the patent and the nature of the dispute, the following terms will likely be central to claim construction.

  • The Term: "crystalline form of polymorph I"

  • Context and Importance: This term is the foundation of the asserted product claims (e.g., claim 14). The entire case hinges on its definition. Whether Apotex's product infringes, and whether the claims are valid over the prior art, will depend on what falls within the scope of "polymorph I."

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: Plaintiffs may argue that "polymorph I" should be defined broadly by its functional characteristics and analytical data provided in the patent. The specification characterizes the form by its melting point, as well as its X-ray, IR, and Raman spectra, suggesting that any material exhibiting these properties is "polymorph I," regardless of minor process variations RE'826 Patent, col. 14:26-44 RE'826 Patent, col. 15:1-24
    • Evidence for a Narrower Interpretation: Defendants may argue that "polymorph I" is inextricably linked to the specific, novel crystallization process disclosed to achieve it RE'826 Patent, col. 14:1-25 They might contend that only the exact form produced by that specific process qualifies, and any deviation results in a different, non-infringing material.

  • The Term: "prepared by a process comprising..."

  • Context and Importance: This phrase appears in product-by-process claims like claim 27. Under U.S. patent law, process steps in a product-by-process claim are treated as limitations upon the claim for infringement purposes. Practitioners may focus on this term because it creates a high evidentiary bar for the plaintiff.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: Plaintiffs may focus on the word "comprising," arguing that the listed steps are merely a required part of the process, which could include other, unlisted steps. They may also argue the process imparts unique and non-obvious structural characteristics to the final product, attempting to broaden the infringement read.
    • Evidence for a Narrower Interpretation: Defendants will likely argue that this language requires Plaintiffs to prove, on an element-by-element basis, that Defendants' manufacturing process includes each recited step RE'826 Patent, col. 57:59 - col. 58:20 The absence of even one step in Defendants' process would support a finding of non-infringement for this claim.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that if its ANDA is approved, Apotex will induce and contribute to infringement by healthcare professionals and patients Compl. ¶56 Compl. ¶64 The basis for this allegation is that Apotex knows and intends for its generic product to be used in accordance with its label, which will direct an infringing use Compl. ¶64
  • Willful Infringement: The complaint alleges that Apotex acted with "full knowledge of the RE'826 Patent" and "without a reasonable basis for believing" its product would not infringe Compl. ¶57 This allegation is predicated on Apotex's filing of a Paragraph IV certification and its receipt of information about the patent, forming the basis for a potential claim for enhanced damages.

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of physical identity: Does the active ingredient in Apotex's proposed generic product, as described in its ANDA and as it would be manufactured, meet the specific structural and analytical definitions of "crystalline form of polymorph I" as claimed in the RE'826 Patent? The outcome will depend heavily on expert analysis of scientific data obtained during discovery.
  • A second key question will be the validity of the polymorph claims: Assuming Apotex's product is found to be the claimed polymorph, was that specific crystalline form novel and non-obvious over the prior art at the time of invention? The patent argues this polymorph is a specific discovery, while Apotex's invalidity defense, noted in the complaint, will likely challenge this assertion.
  • An evidentiary question will center on the product-by-process claims: For claims that include process limitations (e.g., Claim 27), can Bayer produce evidence that Apotex's confidential manufacturing process actually performs the specific steps required by the claim, a necessary condition for proving infringement of such claims?
Loading Complaint